Developer docs
API playgroundTry for free, no card

Search company profiles

Alcresta

Full company profile

uuid0000ipn

Namestring
Alcresta
Legal namestring
Alcresta Therapeutics, Inc.
Websiteurl
alcresta.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Alcresta Therapeutics, Inc. is a private, commercial-stage medical device and specialty nutrition company that develops enzyme-based products addressing fat malabsorption in enterally fed patients with rare and serious diseases. The company's lead and only commercial product, RELiZORB, is an in-line digestive enzyme cartridge that uses Alcresta's proprietary iLipase enzyme immobilization platform — lipase bound to polymeric microbead carriers contained within a cartridge that connects to enteral feeding tubing. As enteral formula passes through the cartridge, the immobilized lipase hydrolyzes triglycerides into absorbable fatty acids and monoglycerides prior to ingestion, while the enzymes themselves remain in the device and are not consumed by the patient.

RELiZORB is the first and only FDA-cleared enzyme product for enteral feeding, originally approved via de novo pathway in 2015 for adults and progressively expanded to children age 5+ (2017), age 2+ (August 2023), age 1+ (January 2025), and ultimately all ages including neonates and infants (April 2025). A next-generation device with broader formula compatibility and support for up to six cartridges per day was launched in May 2024. Alcresta is also developing RELiZORBneo, a smaller cartridge specifically engineered for neonatal small-volume, slow-flow feeding in the NICU. The company generates revenue primarily through direct hardware sales to hospitals, clinics, and home healthcare/DME channels, with separate Medicare Part B reimbursement under permanent HCPCS code B4105 (effective January 2019).

Alcresta sells through an enterprise field sales model targeting hospitals, outpatient clinics, and home settings, with an emphasis on physician, dietitian, and nurse education supported by an expanding peer-reviewed clinical evidence library and investigator-initiated trials at Massachusetts General Hospital, Inova Fairfax, and Boston Children's Hospital. The company is backed by private equity firms Linden Capital Partners and HealthQuest Capital, with prior venture backing from Bessemer Venture Partners, Frazier Healthcare Partners, and Third Rock Ventures. Headquartered in Waltham, Massachusetts, Alcresta operates with 11-50 employees under CEO Daniel Orlando, with a senior leadership bench that includes executives previously at Vericel, Boston Scientific, Pfizer, Novartis, and other major life sciences firms.

Short descriptiontext

Alcresta Therapeutics is a private, commercial-stage medical device company that develops enzyme-based products for fat malabsorption in enterally fed patients with cystic fibrosis, short bowel syndrome, pancreatitis, and neonatal conditions, led by its FDA-cleared RELiZORB cartridge built on the proprietary iLipase immobilization platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enteral nutrition devices, digestive enzyme cartridges, fat malabsorption treatment, medical device enteral feeding, enzyme immobilization technology
Industry3 codes
PRIMARYAFAHAHAC
Special Medical Purpose Infant Formula Manufacturing (FSMP/Medical Nutrition)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAHAHAD
Hypoallergenic & Allergy-Friendly Infant Formula Manufacturing (Extensively Hydrolyzed/Amino Acid)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYHSADAFAH
Gut Health & Digestive Nutrition (IBS, GERD, Elimination Diets)
NAICS code1 code
  • Food Manufacturing311
SIC code1 code
  • Food And Kindred Products2000
Product category
Enteral Nutrition Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1RELiZORB Device Sales
TypeHardware Sales
Description

Commercial sales of RELiZORB digestive enzyme cartridge for enteral feeding patients with fat malabsorption conditions. Sold to hospitals, clinics, and directly to patients via home healthcare.

alcresta.com
2Medicare/Insurance Reimbursement
TypeHardware Sales
Description

RELiZORB received permanent HCPCS billing code B4105 effective January 1, 2019. The Medicare coverage indicator is 'C' (Contractor Discretion) with pricing indicator '39' (Parenteral and Enteral Nutrition), enabling separate reimbursement under Medicare rules.

alcresta.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations, Infrastructure
Pricing details1 tier
1RELiZORB covered under Medicare Part B with unique HCPCS code B4105
ModelOtherBilling cadencePay-as-you-go
Notes

HCPCS Code B4105: 'In-Line Cartridge Containing Digestive Enzymes(s) for Enteral Feeding, Each'. Medicare pricing indicator: 39 (Parenteral and Enteral Nutrition). Coverage: Contractor Discretion.

alcresta.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1RELiZORB
Description

The first and only FDA-cleared enzyme cartridge for use in enteral feeding, designed to mimic pancreatic lipase function to improve fat absorption for tube-fed patients.

alcresta.com
+2 more records
Core offering1 text field

Alcresta develops and commercializes RELiZORB, an FDA-cleared single-use digestive enzyme cartridge that connects in-line to enteral feeding tubes. Using its proprietary iLipase enzyme immobilization platform, the cartridge pre-digests fats in enteral formula into absorbable fatty acids and monoglycerides prior to ingestion for patients with fat malabsorption conditions including cystic fibrosis, short bowel syndrome, pancreatitis, and neonatal pancreatic insufficiency.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 2.8x overall increase in total DHA and EPA plasma concentrations in 24-hour study
+7 more records
Product and service2 records
1RELiZORB Digestive Enzyme Cartridge
CategoryEnteral nutrition medical device
Description

A single-use, FDA-cleared digestive enzyme cartridge designed to mimic the function of pancreatic lipase. Connects in-line to enteral feeding tubes so that as enteral formula passes through, the bound iLipase enzyme breaks down fats into absorbable fatty acids and monoglycerides prior to ingestion. Indicated for children and adults with fat malabsorption due to cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, neonatal pancreatic insufficiency, and other rare diseases.

2RELiZORBneo Cartridge
CategoryEnteral nutrition medical device (pipeline)
Description

A miniaturized version of the RELiZORB cartridge under development, designed to align with tube-feeding practices in neonatal intensive care for premature and newborn infants who cannot adequately digest fats due to pancreatic immaturity.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Collaborative research partnership for preclinical studies. Team led by Mark Puder, M.D., PhD, world-leading expert in short bowel syndrome and parenteral/enteral nutrition. Conducted neonatal murine NEC model study and pre-clinical animal studies in SBS.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-16
Description

Investigator-initiated trial evaluating efficacy of RELiZORB in treatment of feeding intolerance in critically ill patients with multi-organ failure. Led by George J. Kasotakis, MD, MPH, Trauma/Acute Care Surgeon.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Investigator-initiated clinical trial evaluating efficacy of RELiZORB in managing exocrine pancreatic insufficiency in tube-fed pancreatitis patients. Located at MGH Pancreatitis Treatment Center, led by Casey Luckhurst, MD.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Markets Creon, the leading oral pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency. Most relevant comparator for the underlying EPI/fat-malabsorption therapeutic category, though delivery mechanism (oral capsules vs. Alcresta's in-line cartridge) differs.

TypeBroad incumbent
Description

Major enteral nutrition provider (Peptamen, Vivonex, Impact) and a logical strategic/partner candidate for Alcresta. Comparable through shared enteral-feeding end customers and overlapping CF, SBS, and critical-care channels.

TypeBroad incumbent
Description

Supplies enteral formulas (Jevity, Pivot, Nepro, Pulmocare) used by the same patient populations Alcresta targets. Strong commercial reach in hospitals, home health, and pediatric specialty channels overlapping with RELiZORB's customer base.

TypeBroad incumbent
Description

Operates a leading enteral/parenteral nutrition portfolio (Clinimix, Clinolipid, Numeta) and serves hospitals and home infusion. Highly relevant as a strategic acquirer given its enteral-nutrition franchise and prior relationship with Alcresta board (Ron Labrum spent 25+ years at Baxter).

TypeBroad incumbent
Description

Major medical-nutrition business focused on disease-specific enteral formulas for pediatric and adult populations, including CF and SBS. Comparable patient segments, sales channels, and reimbursement dynamics to RELiZORB.

TypeDirect peer
Description

Zenpep is a leading oral PERT for EPI. Closest therapeutic competitor to RELiZORB for the underlying EPI patient, though the delivery mechanism (oral) and patient profile (typically not enterally fed) differ.

TypeDirect peer
Description

Markets Pertzye, an oral PERT for EPI caused by CF and other conditions. Direct therapeutic competitor addressing the same fat-malabsorption indication that RELiZORB targets in enterally-fed patients.

TypeDirect peer
Description

Specializes in enteral feeding devices (tubes, pumps, accessories) used by the same patient populations as RELiZORB. Comparable go-to-market via hospital purchasing, specialty pharmacies, and home-health DME channels.

TypeDirect peer
Description

Medical devices segment includes enteral feeding pumps (Infinity) and disposables for tube-fed patients in hospital and home settings. Most directly comparable medical-device peer in terms of product category and customer profile.

TypeEmerging player
Description

Emerging participant in the enteral-feeding space focused on whole-food, blenderized tube-feeding formulas. Adjacent rather than directly competitive, but addresses the same enterally-fed patient base seeking improved fat/nutrient absorption.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alcresta

Enteral Nutrition Medical Devicesalcresta.com

Alcresta Therapeutics is a private, commercial-stage medical device company that develops enzyme-based products for fat malabsorption in enterally fed patients with cystic fibrosis, short bowel syndrome, pancreatitis, and neonatal conditions, led by its FDA-cleared RELiZORB cartridge built on the proprietary iLipase immobilization platform.

What Alcresta does

Alcresta Therapeutics, Inc. is a private, commercial-stage medical device and specialty nutrition company that develops enzyme-based products addressing fat malabsorption in enterally fed patients with rare and serious diseases. The company's lead and only commercial product, RELiZORB, is an in-line digestive enzyme cartridge that uses Alcresta's proprietary iLipase enzyme immobilization platform — lipase bound to polymeric microbead carriers contained within a cartridge that connects to enteral feeding tubing. As enteral formula passes through the cartridge, the immobilized lipase hydrolyzes triglycerides into absorbable fatty acids and monoglycerides prior to ingestion, while the enzymes themselves remain in the device and are not consumed by the patient.

RELiZORB is the first and only FDA-cleared enzyme product for enteral feeding, originally approved via de novo pathway in 2015 for adults and progressively expanded to children age 5+ (2017), age 2+ (August 2023), age 1+ (January 2025), and ultimately all ages including neonates and infants (April 2025). A next-generation device with broader formula compatibility and support for up to six cartridges per day was launched in May 2024. Alcresta is also developing RELiZORBneo, a smaller cartridge specifically engineered for neonatal small-volume, slow-flow feeding in the NICU. The company generates revenue primarily through direct hardware sales to hospitals, clinics, and home healthcare/DME channels, with separate Medicare Part B reimbursement under permanent HCPCS code B4105 (effective January 2019).

Alcresta sells through an enterprise field sales model targeting hospitals, outpatient clinics, and home settings, with an emphasis on physician, dietitian, and nurse education supported by an expanding peer-reviewed clinical evidence library and investigator-initiated trials at Massachusetts General Hospital, Inova Fairfax, and Boston Children's Hospital. The company is backed by private equity firms Linden Capital Partners and HealthQuest Capital, with prior venture backing from Bessemer Venture Partners, Frazier Healthcare Partners, and Third Rock Ventures. Headquartered in Waltham, Massachusetts, Alcresta operates with 11-50 employees under CEO Daniel Orlando, with a senior leadership bench that includes executives previously at Vericel, Boston Scientific, Pfizer, Novartis, and other major life sciences firms.

Alcresta firmographics

Firmographics
Name
Alcresta
Legal name
Alcresta Therapeutics, Inc.
Website
https://alcresta.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
101–250 employees
Short description
Alcresta Therapeutics is a private, commercial-stage medical device company that develops enzyme-based products for fat malabsorption in enterally fed patients with cystic fibrosis, short bowel syndrome, pancreatitis, and neonatal conditions, led by its FDA-cleared RELiZORB cartridge built on the proprietary iLipase immobilization platform.
Ownership category
akta.pro rank

Alcresta industry classification

Industry
Product category
Enteral Nutrition Medical Devices
NAICS
Food Manufacturing (311)
SIC
Food And Kindred Products (2000)
akta.pro industry
PRIMARYAFAHAHAC
Special Medical Purpose Infant Formula Manufacturing (FSMP/Medical Nutrition)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYAFAHAHAD
Hypoallergenic & Allergy-Friendly Infant Formula Manufacturing (Extensively Hydrolyzed/Amino Acid)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
SECONDARYHSADAFAH
Gut Health & Digestive Nutrition (IBS, GERD, Elimination Diets)

Keywords

  • Enteral nutrition devices
  • Digestive enzyme cartridges
  • Fat malabsorption treatment
  • Medical device enteral feeding
  • Enzyme immobilization technology

Where Alcresta is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Alcresta business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations, Infrastructure

Revenue model

  1. RELiZORB Device Sales: Commercial sales of RELiZORB digestive enzyme cartridge for enteral feeding patients with fat malabsorption conditions. Sold to hospitals, clinics, and directly to patients via home healthcare.
  2. Medicare/Insurance Reimbursement: RELiZORB received permanent HCPCS billing code B4105 effective January 1, 2019. The Medicare coverage indicator is 'C' (Contractor Discretion) with pricing indicator '39' (Parenteral and Enteral Nutrition), enabling separate reimbursement under Medicare rules.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goRELiZORB covered under Medicare Part B with unique HCPCS code B4105

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Alcresta product offering

Product offering

Core offering

Alcresta develops and commercializes RELiZORB, an FDA-cleared single-use digestive enzyme cartridge that connects in-line to enteral feeding tubes. Using its proprietary iLipase enzyme immobilization platform, the cartridge pre-digests fats in enteral formula into absorbable fatty acids and monoglycerides prior to ingestion for patients with fat malabsorption conditions including cystic fibrosis, short bowel syndrome, pancreatitis, and neonatal pancreatic insufficiency.

Differentiator

Problem solved

Functional benefit

Brands

  • RELiZORB: The first and only FDA-cleared enzyme cartridge for use in enteral feeding, designed to mimic pancreatic lipase function to improve fat absorption for tube-fed patients.
  • RELiZORBneo
  • iLipase

Products and services

  • RELiZORB Digestive Enzyme Cartridge A single-use, FDA-cleared digestive enzyme cartridge designed to mimic the function of pancreatic lipase. Connects in-line to enteral feeding tubes so that as enteral formula passes through, the bound iLipase enzyme breaks down fats into absorbable fatty acids and monoglycerides prior to ingestion. Indicated for children and adults with fat malabsorption due to cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, neonatal pancreatic insufficiency, and other rare diseases.
  • RELiZORBneo Cartridge A miniaturized version of the RELiZORB cartridge under development, designed to align with tube-feeding practices in neonatal intensive care for premature and newborn infants who cannot adequately digest fats due to pancreatic immaturity.

Quantifiable outcome

  • 2.8x overall increase in total DHA and EPA plasma concentrations in 24-hour study
  • +7 more outcomes

Companies that use Alcresta

Customer profile

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Alcresta technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Alcresta partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Boston Children's HospitalcoreStrategic or Co-development Partner · 1 May 2026Collaborative research partnership for preclinical studies. Team led by Mark Puder, M.D., PhD, world-leading expert in short bowel syndrome and parenteral/enteral nutrition. Conducted neonatal murine NEC model study and pre-clinical animal studies in SBS.
  • Inova Fairfax Medical CampuscoreStrategic or Co-development Partner · 16 June 2025Investigator-initiated trial evaluating efficacy of RELiZORB in treatment of feeding intolerance in critically ill patients with multi-organ failure. Led by George J. Kasotakis, MD, MPH, Trauma/Acute Care Surgeon.
  • Massachusetts General HospitalcoreStrategic or Co-development Partner · 29 April 2025Investigator-initiated clinical trial evaluating efficacy of RELiZORB in managing exocrine pancreatic insufficiency in tube-fed pancreatitis patients. Located at MGH Pancreatitis Treatment Center, led by Casey Luckhurst, MD.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Alcresta competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Markets Creon, the leading oral pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency. Most relevant comparator for the underlying EPI/fat-malabsorption therapeutic category, though delivery mechanism (oral capsules vs. Alcresta's in-line cartridge) differs.
  • Nestlé Health Science: Major enteral nutrition provider (Peptamen, Vivonex, Impact) and a logical strategic/partner candidate for Alcresta. Comparable through shared enteral-feeding end customers and overlapping CF, SBS, and critical-care channels.
  • Abbott Nutrition: Supplies enteral formulas (Jevity, Pivot, Nepro, Pulmocare) used by the same patient populations Alcresta targets. Strong commercial reach in hospitals, home health, and pediatric specialty channels overlapping with RELiZORB's customer base.
  • Baxter International: Operates a leading enteral/parenteral nutrition portfolio (Clinimix, Clinolipid, Numeta) and serves hospitals and home infusion. Highly relevant as a strategic acquirer given its enteral-nutrition franchise and prior relationship with Alcresta board (Ron Labrum spent 25+ years at Baxter).
  • Danone Nutricia: Major medical-nutrition business focused on disease-specific enteral formulas for pediatric and adult populations, including CF and SBS. Comparable patient segments, sales channels, and reimbursement dynamics to RELiZORB.

Direct peers

  • Allergan Aesthetics / AbbVie (Zenpep): Zenpep is a leading oral PERT for EPI. Closest therapeutic competitor to RELiZORB for the underlying EPI patient, though the delivery mechanism (oral) and patient profile (typically not enterally fed) differ.
  • Digestive Care (Pertzye): Markets Pertzye, an oral PERT for EPI caused by CF and other conditions. Direct therapeutic competitor addressing the same fat-malabsorption indication that RELiZORB targets in enterally-fed patients.
  • Vygon: Specializes in enteral feeding devices (tubes, pumps, accessories) used by the same patient populations as RELiZORB. Comparable go-to-market via hospital purchasing, specialty pharmacies, and home-health DME channels.
  • Moog Inc. Medical devices segment includes enteral feeding pumps (Infinity) and disposables for tube-fed patients in hospital and home settings. Most directly comparable medical-device peer in terms of product category and customer profile.

Emerging players

  • Real Food Blends: Emerging participant in the enteral-feeding space focused on whole-food, blenderized tube-feeding formulas. Adjacent rather than directly competitive, but addresses the same enterally-fed patient base seeking improved fat/nutrient absorption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Alcresta social profiles

Digital presence

Alcresta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alcresta leadership team

Management profile

Number of profiles

Profiles15 records

Alcresta funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alcresta M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alcresta

What does Alcresta do?

Alcresta develops and commercializes RELiZORB, an FDA-cleared single-use digestive enzyme cartridge that connects in-line to enteral feeding tubes. Using its proprietary iLipase enzyme immobilization platform, the cartridge pre-digests fats in enteral formula into absorbable fatty acids and monoglycerides prior to ingestion for patients with fat malabsorption conditions including cystic fibrosis, short bowel syndrome, pancreatitis, and neonatal pancreatic insufficiency.

Is Alcresta a public or private company?

Alcresta is a private company. It is classified as private equity controlled and is currently operating.

When was Alcresta founded?

Alcresta was founded in 2010. It employs 101 to 250 people.

Where is Alcresta based?

Alcresta is headquartered in Waltham, United States, in the North America region.

How does Alcresta make money?

Two revenue lines are on record. RELiZORB Device Sales are the primary driver. The others are medicare/Insurance Reimbursement.

Who are Alcresta's main competitors?

Broad incumbents on record are AbbVie, Nestlé Health Science, Abbott Nutrition, Baxter International and Danone Nutricia. Direct peers are Allergan Aesthetics / AbbVie (Zenpep), Digestive Care (Pertzye), Vygon and Moog Inc.. Real Food Blends is listed as an emerging player.

Does Alcresta have an API?

No public API is recorded for Alcresta.

What industry is Alcresta in?

Alcresta's product category is Enteral Nutrition Medical Devices. Its primary akta.pro industry code is AFAHAHAC, Special Medical Purpose Infant Formula Manufacturing (FSMP/Medical Nutrition), with a secondary code of AFAHAHAD, Hypoallergenic & Allergy-Friendly Infant Formula Manufacturing (Extensively Hydrolyzed/Amino Acid). Its NAICS code is 311 and its SIC code is 2000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAlcresta Therapeutics Announces Preclinical Data Evaluating RELiZORBneo Cartridge Use in Neonatal Murine Model of Necrotizing EnterocolitisAlcresta Therapeutics announced preclinical data from a study conducted at Boston Children's Hospital showing that its RELiZORBneo immobilized lipase cartridge demonstrated statistically significant improvements in clinical sickness, intestinal appearance, and histologic severity scores in a neonatal murine model of necrotizing enterocolitis compared to placebo. The study found that pre-digesting fats in enteral nutrition with RELiZORBneo was associated with potential safety benefits by modulating NEC severity, though survival and weight differences were not statistically significant in this short-duration exploratory model. RELiZORBneo is a smaller version of Alcresta's existing RELiZORB product, which has been on the market since 2015, and is being developed to support tube-fed neonates and infants who require small volumes and frequent feeding schedules.BioSpaceAlcresta Therapeutics Announces Preclinical Data Evaluating RELiZORBneo Cartridge Use in Neonatal Murine Model of Necrotizing EnterocolitisAlcresta Therapeutics published preclinical data from a Boston Children's Hospital study on RELiZORBneo in a neonatal necrotizing enterocolitis murine model. The study found statistically significant improvements in sickness, intestinal appearance, and histologic severity, but survival and weight differences were not statistically significant. The company plans to seek FDA clearance for the product.PR NewswireAlcresta Therapeutics Announces Publication of Real-World Evidence Showing Improvements in Growth for Children Ages 1 to 5 Years Old With Use of RELiZORB®Alcresta Therapeutics announced publication of real-world evidence in the journal Nutrients demonstrating statistically significant improvements in weight and BMI z-scores for children ages 1 to 5 years old who used RELiZORB over a 12-month period, with improvements visible as early as 3 months. The retrospective evaluation found no new safety concerns, with about three-fourths of the analyzed patients having cystic fibrosis and the remaining quarter having other malabsorptive conditions. This study builds upon existing clinical evidence supporting RELiZORB's effectiveness and expands the body of real-world data informing nutritional care decisions for pediatric tube-fed patients.PR NewswireAlcresta Therapeutics Announces Enrollment of First Patient in Clinical Trial Evaluating Use of RELiZORB in Pancreatitis Patients at Massachusetts General HospitalAlcresta Therapeutics announced that Massachusetts General Hospital has enrolled the first patient in an investigator-initiated clinical trial evaluating the efficacy of RELiZORB in managing exocrine pancreatic insufficiency (EPI) in tube-fed pancreatitis patients. RELiZORB is the only FDA-cleared enzyme device designed to mimic pancreatic lipase function to improve fat absorption in tube-fed patients. This trial is one of four clinical trials Alcresta is conducting to expand clinical evidence supporting RELiZORB use in malabsorptive conditions including pancreatitis, cystic fibrosis, and short bowel syndrome.PR NewswireAlcresta Therapeutics Announces Commercial Availability of Next-Generation RELiZORB® (iMMOBILIZED LIPASE) CartridgeAlcresta Therapeutics announced the commercial availability of its next-generation RELiZORB (iMMOBILIZED LIPASE) cartridge on May 13, 2024, following FDA clearance by the Center for Devices and Radiological Health in December 2023. The updated device expands on the predicate product by offering broader enteral formula compatibility, use in both continuous and bolus-feeding setups, and increases the maximum daily cartridge usage from two to six. The company has simultaneously expanded its sales force from 21 territories in three regions to 27 territories in four regions to address the broader enteral nutrition market.LindenLinden Invests in Alcresta TherapeuticsLinden Capital Partners completed the acquisition of Alcresta Therapeutics, a developer of enzyme-based products for gastrointestinal disorders and rare diseases. This investment coincides with Alcresta receiving 510(k) clearance from the FDA for its next-generation RELiZORB cartridge, which is scheduled to launch in Q2 2024.AlcrestaLinden Capital Partners Acquires Alcresta Therapeutics, Inc.Linden Capital Partners completed its acquisition of Alcresta Therapeutics from Athyrium Capital, Bessemer Venture Partners, Frazier Healthcare Partners, and HealthQuest Capital. This transaction coincides with Alcresta receiving 510(k) clearance from the FDA for its next-generation RELiZORB cartridge, which is expected to launch in Q2 2024.Venture Capital Access OnlineLinden Capital Partners Acquires Alcresta Therapeutics, Inc.Linden Capital Partners has completed the acquisition of Alcresta Therapeutics from Athyrium Capital, Bessemer Venture Partners, Frazier Healthcare Partners, and HealthQuest Capital. This transaction follows Alcresta's recent FDA 510(k) clearance for its next-generation RELiZORB cartridge, which is scheduled to launch in Q2 2024. Linden will support Alcresta's growth through a new board assembly focused on healthcare expertise and commercial execution.PR NewswireLinden Capital Partners Acquires Alcresta Therapeutics, Inc.Linden Capital Partners has completed the acquisition of Alcresta Therapeutics from Athyrium Capital, Bessemer Venture Partners, Frazier Healthcare Partners, and HealthQuest Capital. This transaction follows Alcresta's recent FDA 510(k) clearance for its next-generation RELiZORB cartridge, which is scheduled to launch in Q2 2024.PR NewswireAlcresta Therapeutics Announces FDA Expanded Use Clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Pediatric Patients Ages 2 to 5 YearsAlcresta Therapeutics announced that the U.S. Food and Drug Administration has cleared expanded use of RELiZORB, a digestive enzyme cartridge for enteral feeding, to children ages 2 to under 5 years. The device, originally FDA-cleared for adults in 2015 and children five and older in 2017, is the only enzyme product cleared by the FDA for use with enteral feeding. This clearance opens access to approximately 25% of the cystic fibrosis enterally fed market, addressing fat malabsorption in pediatric patients with conditions like exocrine pancreatic insufficiency.